Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

Vieira, Andréa; Fang, Chia Bin; Rolim, Ernani Geraldo; Klug, Wilmar Artur; Steinwurz, Flávio; Rossini, Lucio G.; Candelária, Paulo Azevedo

doi:10.1186/1756-0500-2-221

Cited by 107 publications

(86 citation statements)

References 27 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concentrations between 0 and 50 mg/kg of stool were treated as normal values; positive result meant that the concentration was above 50 mg/kg of feces (norm I = NI). In active inflammatory bowel disease concentration of calprotectin is usually between 200 and 20,000 mg/kg of feces, what was regarded as a norm II (NII) [2,9,17].…”

Section: Methodsmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment. Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation. Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn's disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured. Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group. Conclusions. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn's disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD (Adv Clin Exp Med 2015, 24, 5, 815-822).

show abstract

Section: Methodsmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…8,9 FC is more sensitive than CDAI or CRP at detecting endoscopic inflammation, 9,14 and is a reliable surrogate marker of mucosal healing in patients with Crohn's disease. 8,15 Increased FC concentrations are associated with an increased risk of clinical relapse.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

et al. 2015

View full text Add to dashboard Cite

and PV Desmond have no conflicts of interest to declare. P De Cruz has received travel grant support from Abbott and Schering-Plough. MA Kamm has acted as an advisor to Abbott and Janssen, has received research support from Abbott, and has acted as a speaker at symposiums sponsored by Abbott and Janssen. A Hamilton has received an educational grant from Abbott. D Liew has served on advisory boards and received research grants from Abbott. IC Lawrance has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and has held research and travel grants from Abbott and Janssen. JM Andrews has been an advisory board member for both Janssen and Abbott, spoken for both Abbott and Janssen, received research funds from both Abbott and Janssen, and received travel grants from both Abbott and Janssen. PA Bampton has been on advisory boards for Janssen and Abbott, has received research funding from Abbott, and travel sponsorship from both Abbott and Janssen. PR Gibson has received consulting fees from Abbott, Janssen, and Schering-Plough; research support from Abbott; and payments for lectures from Abbott and Janssen. FA Macrae has been on an advisory board to Janssen, has received travel grants from Abbott, and has received clinical research support from Janssen, Abbott and MSD. W Selby has been on an advisory board for Abbott. SJ Bell has received travel assistance from Abbott. SJ Brown has received travel support and speaker fees from both Abbott and Janssen. WR Connell has been on advisory board for Janssen and a speaker for Abbott and Janssen. AS Day has been an M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT advisor to Janssen. RB Gearry has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and held research, educational and travel grants from Abbott and Janssen.

show abstract

“…Clinical activity indices and serum inflammatory markers correlate poorly with endoscopic disease activity [9,17,18,21]. Fecal calprotectin, which is excreted by migrating neutrophils to the lumen of the inflamed bowel, has been demonstrated a useful surrogate marker for disease activity in both children and adults [18,21,22,31,32]. However, FC is not specific to inflammatory bowel disease and may increase in the presence of other gastrointestinal disorders, such as infectious colitis and polyposis [33,34].…”

Section: Discussionmentioning

confidence: 99%

“…Despite resolution of active mucosal inflammation during medical therapy for CD, FC levels may remain elevated reflecting persistent microscopic inflammation of the bowel wall [17,18,21,22,31,32]. Suggested cutoff values for detection of relapse vary between 150 and 275 μg/g, usually with moderate sensitivity but good specificity [17,18,21,32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents

Hukkinen

Pakarinen

Merras‐Salmio

et al. 2016

Journal of Pediatric Surgery

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oBackground: Fecal calprotectin (FC) correlates with endoscopic recurrence of Crohn's disease (CD) in adults but has not been studied among children postoperatively. We aimed to analyze whether FC relates with postoperative CD recurrence in children. Methods: Altogether 51 postoperative endoscopies and FC measurements from 22 patients having undergone surgery for CD at age ≤18 years were included. Results: Ileocecal resection (n = 15), small bowel resection (n = 6), or left hemicolectomy (n = 1) was performed at median age of 15.1 (interquartile range 14.4-17.6) years. Following surgery, FC decreased significantly (659 vs. 103 μg/g, p = 0.001). During median follow-up of 5.7 (4.2-7.7) years, either endoscopic or histological recurrence occurred in 17 patients (77%). FC N139 μg/g at time of endoscopy or FC increase of 79 μg/g compared to first postoperative value was suggestive of endoscopic recurrence (Rutgeerts score i2-i4), while FC N101 μg/g or increase of 21 μg/g indicated histological recurrence. Best accuracy for prediction of recurrence was obtained by combining FC at endoscopy and the postoperative increase of FC. The corresponding AUROC values were 0.74 (95% 0.58-0.89) for endoscopic recurrence whereas 0.81 (95% CI 0.67-0.95) for histological recurrence. Conclusion: FC is a useful surrogate marker of postoperative recurrence also in pediatric CD patients.

show abstract

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

Cited by 107 publications

References 27 publications

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents

Contact Info

Product

Resources

About